PMN

ProMIS NeurosciencesA

Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences

Quote time unavailable

View Chart

AI scenario view

RankAlpha Sentiment Codex

B+

Bull case

25%

Probability

Target price

$6.80

Analysis reference price unavailable

Analysis 2026-11-04 · RankAlpha Sentiment Codex

Most likely

Base case

40%

Probability

Target price

$3.00

Analysis reference price unavailable

Analysis 2026-11-04 · RankAlpha Sentiment Codex

B-

Bear case

35%

Probability

Target price

$1.20

Analysis reference price unavailable

Analysis 2026-11-04 · RankAlpha Sentiment Codex

The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented

AI sentiment snapshot

Latest data as of 2026-11-04

AI commentary

Monitoring view despite a meaningful upcoming trial readout. The packet provides no verified recent price-reaction, social, options, short-interest, or post-print analyst-revision data; sentiment numeric fields are unavailable, not evidence of neutral readings. The stored October 22 earnings document primarily concerns HCA Healthcare and is not treated as a ProMIS earnings release. The deterministic prior is negative over 5–120 days.

RankAlpha Sentiment Codex - 2026-11-04

Open full AI memo

Evidence flagged

small-cap biotech peer set is too weak or includes unrelated comparators for a standard-conviction report; small-cap biotech memo lacks a distinct long-horizon program, partnership, or financing catalyst for a standard-conviction report

Impact

tentative

Confidence

AI events

2026-12-31catalystPRECISE-AD 12-month dosing completionHigh impact

ProMIS expects all patients to complete dosing in Q4 2026. Completion would support, but not establish, the timetable for the unblinded analysis. [#SEC-8K-2026-08-13]

2027-03-31eventUnblinded PRECISE-AD topline readoutHigh impact

The company expects 12-month Phase 1b results, including cognitive outcomes, in Q1 2027. The favorable blinded safety and pooled biomarker observations do not establish treatment efficacy; the unblinded comparison is decisive. [#SEC-8K-2026-08-13]

View full catalyst timeline

Recommendation

N/A

No formal recommendation provided.

Open AI Memo

As of 2026-11-04 • Updated nightlySource: Internal modelMethodology